2004.9-2007.7，第三军医大学，肿瘤学，  博士

1997.9-2000.7，第三军医大学，病理学，  硕士

1991.9-1996.7，重庆医科大学，临床医学，学士

2023.08-至今， 重庆大学附属江津医院副院长/肿瘤科学科带头人

2021.12-2023.07，重庆大学附属江津医院肿瘤科，主任

2010.11-2021.11，重庆市江津区中心医院肿瘤科，主任

2009.11-2010.11，第三军医大学大坪医院病理科，副主任

2008.10-2009.11，美国M.D. Anderson Cancer Center，博士后

2007.07-2008.10，第三军医大学大坪医院病理科，副主任

2000.08-2004.08，第三军医大学大坪医院病理科，主治医师

1996.07-1997.07，第三军医大学病理学教研室，助教

结直肠癌的基础和转化研究

1. 结直肠癌的转录组、蛋白质组及代谢组等组学研究；

2. 肿瘤细胞和肿瘤微环境相互作用促进结直肠癌侵袭转移及治疗抵抗的分子机制；

3. 结直肠癌纳米诊疗平台构建及应用。

1. Wang X, Xu Z, Wang J, Wu C, Zhang L, Qian C, Luo Y, Gu Y, Wong WT, Xiang D. A Mitochondria-Targeted Biomimetic Nanomedicine Capable of Reversing Drug Resistance in Colorectal Cancer Through Mitochondrial Dysfunction. Adv Sci (Weinh). 2025 Apr;12(13):e2410630.

2. Siqian Cui, Xi Chen, Ping Sheng, Jian Wang, Ke Ding, Chunrong Wu, Yiguo Zhang, Debing Xiang. A bright lipid drop-targeted probe for dual channel visualizing of colorectal cancer. Sensors and Actuators B: Chemical. 2025; 440: 137936.

3. Xiang J, Wang J, Xiao H, Huang C, Wu C, Zhang L, Qian C, Xiang D. Targeting tumor-associated macrophages in colon cancer: mechanisms and therapeutic strategies. Front Immunol. 2025 Mar 21;16:1573917.

4. Qiu L, Wu S, Zhang L, Li W, Xiang D, Kasim V. The biological roles and molecular mechanisms of m6A reader IGF2BP1 in the hallmarks of cancer. Genes Dis.  2025 Feb 20;12(5):101567.

5. Yin J, Pei Z, Wu C, Liu J, Huang J, Xia R, Xiang D. M2 Macrophage-Derived Exosomal circ_0088494 Inhibits Ferroptosis via Promoting H3K4me1 Modification of STEAP3 in Cutaneous Squamous Cell Carcinoma. Mol Carcinog. 2025 Mar;64(3):513-525.

6. Huang C, Wang J, Xiang J, Wu C, Wang F, Chen J, Sun G, Xiang D. The Emerging Role of ADAM 12 Regulates Epithelial-mesenchymal Transition by Activating the Wnt/β-catenin Signaling Pathway in Colorectal Cancer. Recent Pat Anticancer Drug Discov. 2025;20(2):248-259.

7. Wang X, Zhang H, Chen X, Wu C, Ding K, Sun G, Luo Y, Xiang D. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery. Acta Biomater. 2023 Aug;166:42-68.

8. Long S, Wang J, Weng F, Pei Z, Zhou S, Sun G, Xiang D. ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. Front Pharmacol. 2022 Nov 2;13:1005915.

9. Wu C, Sun G, Wang F, Chen J, Zhan F, Lian X, Wang J, Weng F, Li B, Tang W, Quan J, Xiang D. DYRK2 downregulation in colorectal cancer leads to epithelial-mesenchymal transition induction and chemoresistance. Sci Rep. 2022 Dec 28;12(1):22496.

10. Long S, Wang J, Weng F, Xiang D, Sun G. Extracellular Matrix Protein 1 Regulates Colorectal Cancer Cell Proliferative, Migratory, Invasive and Epithelial-Mesenchymal Transition Activities Through the PI3K/AKT/GSK3β/Snail Signaling Axis. Front Oncol. 2022 Apr 27;12:889159.

11. Huang L, Chen J, Quan J, Xiang D. Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis. Bioengineered. 2021 Dec;12(1):3065-3076.

12.  Wu C, Liu X, Li B, Sun G, Peng C, Xiang D. miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B. Mol Med Rep. 2021 Aug;24(2):557.

13. Chen J, Huang L, Quan J, Xiang D. TRIM14 regulates melanoma malignancy via PTEN/PI3K/AKT and STAT3 pathways. Aging (Albany NY). 2021 May 11;13(9):13225-13238.

14. Wang F, Sun G, Peng C, Chen J, Quan J, Wu C, Lian X, Tang W, Xiang D. ZEB1 promotes colorectal cancer cell invasion and disease progression by enhanced LOXL2 transcription. Int J Clin Exp Pathol. 2021 Jan 1;14(1):9-23.

15. Wu C, Li B, Sun G, Peng C, Xiang D. Efficacy and Safety of Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Onco Targets Ther. 2020 Sep 29;13:9657-9666.

16. Wang F, Chen J, Xiang D, Lian X, Wu C, Quan J. Ellagic acid inhibits cell proliferation, migration, and invasion in melanoma via EGFR pathway. Am J Transl Res. 2020 May 15;12(5):2295-2304.

17. Lian X, Xiang D, Peng C, Chen J, Liao M, Sun G, Zhang Z. DDX49 is a novel biomarker and therapeutic target for lung cancer metastases. J Cell Mol Med. 2020 Jan;24(1):1141-1145.

18. Wu C, Li B, Sun G, Peng C, Xiang D. Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly. Onco Targets Ther. 2018 Oct 8;11:6617-6624.

19. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol. 2014 Sep;45(9):1951-6.

20. Xie J, Xiang DB, Wang H, Zhao C, Chen J, Xiong F, Li TY, Wang XL. Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells. PLoS One. 2012;7(9):e45617.

1. 重庆市自然科学基金重点项目：LOXL2/DDR1重塑ECM促进结直肠癌转移的分子机制及逆转策略。2025-2027。40万。

2. 重庆市教育委员会科学技术研究重大项目：仿生型纳米铂前药重塑基质屏障改善结直肠癌免疫治疗的研究。2024-2027。10万。

3. 津医科研领军项目：ECM1通过PARP1/NF-κB通路重塑结直肠癌免疫抑制微环境的作用及机制研究。2024- 2026年, 20万。

4. 北京市希思科临床肿瘤学研究基金会科研项目：替雷利珠单抗联合贝伐珠单抗和化疗治疗RAS突变mCRC的II期临床研究。2024- 2026年, 10万。

5. 重庆英才计划“包干制”项目：ECM调控EMT在结直肠癌侵袭转移及耐药中的作用及分子机制。2022- 2024年, 40万（配套80万）。

6. 中央高校基本科研业务费医工融合专项：靶向LOXL2纳米组装体逆转结直肠免疫治疗抵抗的研究。2023- 2025年, 60万。

7. 重庆市自然科学基金：DYRK2调控EMT在大肠癌化疗耐药中的作用及分子机制。2020- 2022年, 20万。

8. 国家自然科学基金面上项目：CAPE抑制EMT信号途径逆转大肠癌耐药性的分子机制。2010-2012年，36万。

9. 国家自然科学基金青年基金：CAPE阻断大肠癌异常APC-β-catenin-Tcf-4通路的分子机制。2002-2004年，17万。

10. 重庆市自然科学基金：大肠癌异常APC-β-catenin-Tcf-4通路的分子机理。2002-2004年，2万。

11. 重庆市自然科学基金：β-catenin/Snail信号途径在大肠癌耐药中的作用及机制。2011-2013年，3万。

12. 重庆市卫生局科研项目：Tiam1促进大肠癌转移的分子机制。2012-2014年， 5万。